Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 28Myeloproliferative Disorders 21Polycythemia Vera 16Thrombocythemia, Essential 7Neoplasms 7Pancreatic Neoplasms 6Multiple Myeloma 6Leukemia 6Hematologic Diseases 5Myelodysplastic Syndromes 4Graft vs Host Disease 4Colorectal Neoplasms 4Bone Marrow Diseases 4Thrombocytosis 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 3Bronchiolitis Obliterans Syndrome 3Breast Neoplasms 3Prostatic Neoplasms 2Lymphoma 2Uveal Melanoma 1Thalassemia 1Recurrence 1Preleukemia 1Precancerous Conditions 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1

Interventions

dacetuzumab 2Bortezomib 2sonidegib 1ruxolitinib 1ficlatuzumab 1Vorinostat 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Lenalidomide 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1ARQ531 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hemorrhagic Disorders × ruxolitinib × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡